{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:59:48Z","timestamp":1791604788496,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Improved imaging modalities contributed to increasing awareness of cardiac amyloidosis. Contemporary data on frequency trends in Germany are lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a retrospective study using health claims data of a German statutory health insurance, patients with diagnostic codes of amyloidosis and concomitant heart failure between 2009 and 2018 were identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Prevalence increased from 15.5 to 47.6 per 100,000 person-years, and incidence increased from 4.8 to 11.6 per 100,000 person-years, with a continuous steepening in the slope of incidence trend. In patients with amyloidosis and heart failure age and proportion of men significantly increased, whereas the frequency of myeloma and nephrotic syndrome significantly decreased over time. Median (IQR) survival time after first diagnosis was 2.5\u00a0years (0.5\u20136\u00a0years), with a 9% (95% CI 2\u201315%, <jats:italic>p<\/jats:italic>\u2009=\u20090.008) reduced risk of death in the second compared to the first 5\u00a0years of observation. In the 2\u00a0years prior and 1\u00a0year after diagnosis, mean total health care costs were 6568 \u20ac, 11,872 \u20ac and 21,955 \u20ac per person and year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The rise in cardiac amyloidosis has continuously accelerated in the last decade. Considering the adverse outcome and high health care burden, further effort should be put on early detection of the disease to implement available treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-022-02114-y","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T20:23:34Z","timestamp":1665779014000},"page":"401-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018"],"prefix":"10.1007","volume":"112","author":[{"given":"Svenja","family":"Ney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ihle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"G\u00fcnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Seuthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-5008","authenticated-orcid":false,"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"2114_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135:1357\u20131377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024438","journal-title":"Circulation"},{"key":"2114_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34:520\u2013528. https:\/\/doi.org\/10.1093\/eurheartj\/ehs123","journal-title":"Eur Heart J"},{"key":"2114_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140:16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169","journal-title":"Circulation"},{"key":"2114_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plant\u00e9-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68:161\u2013172. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovi\u0107 ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442\u20131448. https:\/\/doi.org\/10.1136\/heartjnl-2012-302353","journal-title":"Heart"},{"key":"2114_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR7","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"2114_CR8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"2114_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113\u2013122. https:\/\/doi.org\/10.1016\/j.jchf.2013.11.004","journal-title":"JACC Heart Fail"},{"key":"2114_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Sch\u00f6nland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim J-S, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"2114_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"2114_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O\u2019Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"2114_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (2019) Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 12:e005407. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005407","journal-title":"Circ Heart Fail"},{"key":"2114_CR14","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gagliardi C, Dominguez F, Quarta CC, Haro-Del MoralMilandri FJA, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38:1895\u20131904. https:\/\/doi.org\/10.1093\/eurheartj\/ehx043","journal-title":"Eur Heart J"},{"key":"2114_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse R, Bl\u00fcmel M, Knieps F, B\u00e4rnighausen T (2017) Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet 390:882\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(17)31280-1","journal-title":"The Lancet"},{"key":"2114_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","volume":"3","author":"O Westin","year":"2021","unstructured":"Westin O, Butt JH, Gustafsson F, Schou M, Salomo M, K\u00f8ber L, Maurer M, Fosb\u00f8l EL (2021) Two decades of cardiac amyloidosis: a Danish nationwide study. JACC CardioOncol 3:522\u2013533. https:\/\/doi.org\/10.1016\/j.jaccao.2021.05.004","journal-title":"JACC CardioOncol"},{"key":"2114_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","volume":"3","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M (2021) Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol 3:537\u2013546. https:\/\/doi.org\/10.1016\/j.jaccao.2021.08.009","journal-title":"JACC CardioOncol"},{"key":"2114_CR18","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","volume":"8","author":"A Devesa","year":"2021","unstructured":"Devesa A, Camblor Blasco A, Pello L\u00e1zaro AM, Askari E, Lape\u00f1a G, G\u00f3mez Talavera S, Taibo Urqu\u00eda M, Rodr\u00edguez Olleros C, Tu\u00f1\u00f3n J, Ib\u00e1\u00f1ez B, Ace\u00f1a \u00c1 (2021) Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail 8:2856\u20132865. https:\/\/doi.org\/10.1002\/ehf2.13360","journal-title":"ESC Heart Fail"},{"key":"2114_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6:1267\u20131274. https:\/\/doi.org\/10.1001\/jamacardio.2021.3070","journal-title":"JAMA Cardiol"},{"key":"2114_CR20","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1080\/10428194.2021.1913152","volume":"62","author":"G Palladini","year":"2021","unstructured":"Palladini G, Milani P (2021) The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease. Leuk Lymphoma 62:1793\u20131794. https:\/\/doi.org\/10.1080\/10428194.2021.1913152","journal-title":"Leuk Lymphoma"},{"key":"2114_CR21","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","volume":"57","author":"Y Okuda","year":"2018","unstructured":"Okuda Y, Yamada T, Ueda M, Ando Y (2018) First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Intern Med 57:3351\u20133355. https:\/\/doi.org\/10.2169\/internalmedicine.1099-18","journal-title":"Intern Med"},{"key":"2114_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","volume":"27","author":"M Russo","year":"2020","unstructured":"Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G (2020) ATTRv amyloidosis Italian registry: clinical and epidemiological data. Amyloid 27:259\u2013265. https:\/\/doi.org\/10.1080\/13506129.2020.1794807","journal-title":"Amyloid"},{"key":"2114_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126:612\u2013615. https:\/\/doi.org\/10.1182\/blood-2015-01-620302","journal-title":"Blood"},{"key":"2114_CR24","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","volume":"67","author":"BW Sperry","year":"2016","unstructured":"Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, Hanna M (2016) Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67:2941\u20132948. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.593","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ejhf.2028","volume":"23","author":"M B\u00e9zard","year":"2021","unstructured":"B\u00e9zard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Gendre T, Audard V, El Karoui K, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Plant\u00e9-Bordeneuve V, Oghina S, Damy T (2021) Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail 23:264\u2013274. https:\/\/doi.org\/10.1002\/ejhf.2028","journal-title":"Eur J Heart Fail"},{"key":"2114_CR26","unstructured":"Grobe T, Szecsnyi J Arztreport 2021. https:\/\/www.bifg.de\/publikationen\/reporte\/arztreport-2021. Accessed 2 Jan 2022"},{"issue":"Suppl 3","key":"2114_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/1475-6773.13708","volume":"56","author":"JF Figueroa","year":"2021","unstructured":"Figueroa JF, Papanicolas I, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR, Deeny S, Estupi\u00f1\u00e1n-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Shatrov K, van de Galien O, van Gool K, Wodchis W, Jha AK (2021) International comparison of health spending and utilization among people with complex multimorbidity. Health Serv Res 56(Suppl 3):1317\u20131334. https:\/\/doi.org\/10.1111\/1475-6773.13708","journal-title":"Health Serv Res"},{"key":"2114_CR28","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/ehf2.13407","volume":"8","author":"M D\u00f6rr","year":"2021","unstructured":"D\u00f6rr M, Riemer U, Christ M, Bauersachs J, Bosch R, Laufs U, Neumann A, Scherer M, St\u00f6rk S, Wachter R (2021) Hospitalizations for heart failure: Still major differences between East and West Germany 30 years after reunification. ESC Heart Fail 8:2546\u20132555. https:\/\/doi.org\/10.1002\/ehf2.13407","journal-title":"ESC Heart Fail"},{"key":"2114_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0031-1275711","volume":"74","author":"F Hoffmann","year":"2012","unstructured":"Hoffmann F, Icks A (2012) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen f\u00fcr die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 74:291\u2013297. https:\/\/doi.org\/10.1055\/s-0031-1275711","journal-title":"Gesundheitswesen"},{"key":"2114_CR30","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/19.126","author":"AZ Sun","year":"2020","unstructured":"Sun AZ, Shu Y-H, Harrison TN, Hever A, Jacobsen SJ, O\u2019Shaughnessy MM, Sim JJ (2020) Identifying patients with rare disease using electronic health record data: the Kaiser Permanente Southern California Membranous Nephropathy Cohort. Perm J. https:\/\/doi.org\/10.7812\/TPP\/19.126","journal-title":"Perm J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02114-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:05:27Z","timestamp":1678345527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02114-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02114-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not necessary since patient data were completely anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}